Correct ImQE, the race against competition with a mean reduction in the genital lesion rate of only 42 percent below baseline has started. Everyone must be shaking in their boots
http://www.marketwatch.com/story/ge...-for-hsv-2-immunotherapy-at-idweek-2014-10-08
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-58
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.70 |
Change
-0.550(3.86%) |
Mkt cap ! $301.2M | |||
| Open | High | Low | Value | Volume |
| $14.20 | $14.20 | $13.70 | $36.87K | 2.644K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 588 | $14.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.19 | 112 | 1 |
View Market Depth
| Last trade - 10.00am 12/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |